Literature DB >> 29150482

Effect of Mammography Screening on Mortality by Histological Grade.

Laszlo Tabar1, Tony Hsiu-Hsi Chen2, Amy Ming-Fang Yen3, Sam Li-Sheng Chen3, Jean Ching-Yuan Fann4, Sherry Yueh-Hsia Chiu5, May M S Ku2, Wendy Yi-Ying Wu6, Chen-Yang Hsu2, Yu-Ying Chen7, Kerri Beckmann8, Robert A Smith9, Stephen W Duffy10.   

Abstract

Background: It has been asserted that mammography screening preferentially benefits those with less aggressive cancers, with lesser or no impact on more rapidly progressing and therefore more life-threatening tumors.
Methods: We utilized data from the Swedish Two-County Trial, which randomized 77,080 women ages 40 to 74 to invitation to screening and 55,985 for usual care. We tabulated cancers by histologic grade and then compared mortality from cancers specific to histologic grade between the invited and control group using Poisson regression, with specific interest in the effect on mortality from grade 3 cancers. We used incidence-based mortality from tumors diagnosed within the screening phase of the trial. Finally, we cross-tabulated grade with tumor size and node status, to assess downstaging within tumor grades.
Results: There was a major reduction in mortality from grade 3 tumors (RR = 0.65; 95% CI, 0.53-0.80; P < 0.001), and more deaths prevented from grade 3 tumors (n = 95) than grade 1 and 2 tumors combined (n = 48) in the invited group. The proportions of tumors ≥15 mm or larger and node-positive tumors were substantially reduced in the grade 3 tumors in the invited group.Conclusions: The combination of prevention of tumors progressing to grade 3 and detection at smaller sizes and lesser rates of lymph node metastases within grade 3 tumors results in a substantial number of deaths from grade 3 cancers being prevented by invitation to mammographic screening.Impact: Mammography screening prevents deaths from aggressive cancers. Cancer Epidemiol Biomarkers Prev; 27(2); 154-7. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2017        PMID: 29150482     DOI: 10.1158/1055-9965.EPI-17-0487

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  6 in total

1.  Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.

Authors:  Stephen Duffy; Daniel Vulkan; Howard Cuckle; Dharmishta Parmar; Shama Sheikh; Robert Smith; Andrew Evans; Oleg Blyuss; Louise Johns; Ian Ellis; Peter Sasieni; Chris Wale; Jonathan Myles; Sue Moss
Journal:  Health Technol Assess       Date:  2020-10       Impact factor: 4.014

2.  Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis.

Authors:  Johanna Alanko; Minna Tanner; Ritva Vanninen; Anssi Auvinen; Jorma Isola
Journal:  Breast Cancer Res Treat       Date:  2021-01-08       Impact factor: 4.872

3.  The Role of Surgical Axillary Staging Prior to Immediate Breast Reconstruction in the Era of De-Escalation of Axillary Management in Early Breast Cancer.

Authors:  Miriam Svensson; Looket Dihge
Journal:  J Pers Med       Date:  2022-08-04

4.  Radiological audit of interval breast cancers: Estimation of tumour growth rates.

Authors:  Emma G MacInnes; Stephen W Duffy; Julie A Simpson; Matthew G Wallis; Anne E Turnbull; Louise S Wilkinson; Keshthra Satchithananda; Rumana Rahim; David Dodwell; Brian V Hogan; Oleg Blyuss; Nisha Sharma
Journal:  Breast       Date:  2020-04-01       Impact factor: 4.380

5.  Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.

Authors:  Stephen W Duffy; Daniel Vulkan; Howard Cuckle; Dharmishta Parmar; Shama Sheikh; Robert A Smith; Andrew Evans; Oleg Blyuss; Louise Johns; Ian O Ellis; Jonathan Myles; Peter D Sasieni; Sue M Moss
Journal:  Lancet Oncol       Date:  2020-08-12       Impact factor: 41.316

6.  Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy.

Authors:  Karoline Freeman; Julia Geppert; Chris Stinton; Daniel Todkill; Samantha Johnson; Aileen Clarke; Sian Taylor-Phillips
Journal:  BMJ       Date:  2021-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.